Search Results

You are looking at 61 - 70 of 165 items for :

  • "early breast cancer" x
  • All content x
Clear All
Full access

Steven Sorscher

-, node-positive high-risk, early breast cancer (monarchE ). J Clin Oncol 2020 ; 38 : 3987 – 3998 . 4. Press M , Slamon DJ . Controversies in HER2 oncogene testing: what constitutes a true positive result in patients with breast cancer? Letter

Full access

Beryl McCormick

2010 ; 76 : 71 – 78 . 9 Yarnold J Ashton A Bliss J . Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial . Radiother Oncol

Full access

Robert E. Smith Jr.

Johnson D . Vinorelbine plus cisplatin vs. observation in resected non small cell lung cancer . N Engl J Med 2005 ; 352 : 2589 – 2597 . 47. Early Breast Cancer Trialists' Collaborative Group . Polychemotherapy for early breast cancer: an

Full access

Bishal Gyawali and Saroj Niraula

randomization approach to consider in interpretations of such trials. I-SPY 2 is a 20-arm mega randomized controlled trial (RCT) in the neoadjuvant treatment of early breast cancer with the primary endpoint of pathologic complete response (pCR; ClinicalTrials

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

. Biology of Breast Cancer Historically, systemic treatment decisions in early breast cancer were made primarily from an anatomic standpoint, and focused on risk of disease recurrence (prognostic factors) based on tumor size and grade; number of involved

Full access

Jason P. Wilson, David Mattson, and Stephen B. Edge

-conserving surgery with radical mastectomy for early breast cancer . N Engl J Med 2002 : 347 : 1227 – 1232 . 3. Giuliano AE Kirgan DM Guenther JM Morton DL . Lymphatic mapping and sentinel lymphadenectomy for breast cancer . Ann Surg 1994 ; 220

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

hyperplasia treated with tamoxifen. 42 , 43 These data also showed that tamoxifen led to a substantial reduction in the risk of developing benign breast disease. 44 The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview analysis showed that

Full access

Amelia B. Zelnak and Ruth M. O'Regan

Guglielmini P . Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial . Ann Oncol 2006 ; 17 ( Suppl 7 ): vii10 – 14 . 17. Coombes RC Hall E Gibson

Full access

Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis

; 206 : 66 – 75 . 23. McCowan C Shearer J Donnan PT . Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer . Br Med J 2008 ; 99 : 1763 – 1768 . 24. Early Breast Cancer

Full access

Stephen B. Edge

-inferiority phase 3 trial . Lancet 2010 ; 376 : 91 – 102 . 32 Hughes KS Schnaper LA Berry D . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977